| 1.48 -0.03 (-1.99%) | 10-23 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.33 | 1-year : | 2.72 |
| Resists | First : | 2 | Second : | 2.33 |
| Pivot price | 1.37  |
|||
| Supports | First : | 1.26 |
Second : | 0.81 |
| MAs | MA(5) : | 1.54 |
MA(20) : | 1.25 |
| MA(100) : | 1.04 |
MA(250) : | 1.99  |
|
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 56.6 |
D(3) : | 60.8 |
| RSI | RSI(14): 58 |
|||
| 52-week | High : | 4.48 | Low : | 0.7 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ NXL ] has closed below upper band by 39.2%. Bollinger Bands are 173.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 11 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.57 - 1.58 | 1.58 - 1.59 |
| Low: | 1.36 - 1.37 | 1.37 - 1.38 |
| Close: | 1.5 - 1.51 | 1.51 - 1.53 |
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. It licenses and markets Nexalin Device, a non-invasive and drug-free therapy for the treatment of anxiety and insomnia. The company's Nexalin device emits a patented frequency-based waveform, which stimulates a positive response from the mid-brain structures associated with various mental health disorders. It also engages in the development of Generation 2, a medical device that is in clinical trials for the treatment of substance abuse issues related to opiates, chronic pain, Alzheimer's disease, and dementia. The company was incorporated in 2021 and is headquartered in Houston, Texas.
Tue, 21 Oct 2025
Nexalin (Nasdaq: NXL) Reports Cognitive Gains After 30 DIFS Sessions Over 15 Days - Stock Titan
Sat, 18 Oct 2025
Nexalin Technology and BioVie Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - The Register-Guard
Fri, 10 Oct 2025
Nexalin Technology Announces Attendance at the 2025 Maxim Growth Summit - Sahm
Fri, 10 Oct 2025
Oct 22 Attendance — Nexalin at Maxim Growth Summit to Showcase DIFS Neurostimulation & Clinical Data - Stock Titan
Fri, 10 Oct 2025
Is Nexalin Technology (NASDAQ:NXL) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
Thu, 09 Oct 2025
Why Is Nexalin Technology Stock (NXL) Down 20% Today? - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 0 (M) |
| Shares Float | 17 (M) |
| Held by Insiders | 1.47e+007 (%) |
| Held by Institutions | 14.5 (%) |
| Shares Short | 609 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -9e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 296.2 % |
| Return on Equity (ttm) | -138.7 % |
| Qtrly Rev. Growth | 174810 % |
| Gross Profit (p.s.) | 44.78 |
| Sales Per Share | -66.49 |
| EBITDA (p.s.) | 32480.8 |
| Qtrly Earnings Growth | -0.8 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.03 |
| Price to Cash Flow | 15.89 |
| Dividend | 0 |
| Forward Dividend | 124820 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|